Bomedemstat tosylate is under clinical development by Imago BioSciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bomedemstat tosylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bomedemstat tosylate overview
IMG-7289 is under development for the treatment of acute myelogenous leukemia (AML), polycythemia vera, essential thrombocythemia, myelodysplastic syndrome (MDS), myelofibrosis including post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), primary myelofibrosis and new chemical entities for hemoglobinopathies (hemoglobin deficiencies) and solid tumors (other malignances). It is administered through oral route. The drug candidate acts by targeting lysine specific demethylase 1 (LSD-1 or KDM1A).
Imago BioSciences overview
Imago BioSciences is a clinical-stage pharmaceutical company. The company developed lysine-specific demethylase 1(LSD1) inhibitors which help to regulate the growth of bone marrow cells. It develops drugs for acute myeloid leukemia, proliferative diseases, myelofibrosis, polycythemia vera, myelodysplastic syndrome, and essential thrombocythemia. The company is funded by Clarus Ventures, Frazier Healthcare Partners, Amgen Ventures, and Merck Research Laboratories Ventures Fund. It has an operational presence across San Francisco, Boston, and the UK. Imago BioSciences is headquartered in San Francisco, California, the US.
For a complete picture of Bomedemstat tosylate’s drug-specific PTSR and LoA scores, buy the report here.